title: Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells.
abstract: The growth of hormone-responsive MCF7 human breast cancer cells is controlled by steroid hormones and growth factors. By metabolic labeling of cells grown in steroid- and growth factor-stripped serum conditions, we show that insulin-like growth factors (IGF-I and IGF-II) increase by approximately 5-fold the release of several proteins including cathepsin D, alpha 1-antichymotrypsin, and soluble forms of the multifunctional IGF-II/mannose 6-phosphate (M6P) receptor. Two soluble forms of IGF-II/M6P receptors were detected, one major (approximately 260 kilodaltons) and one minor (approximately 85 kilodaltons) that probably represents a proteolytic fragment of the larger soluble molecule. IGFs increased receptor release in a dose-dependent fashion with 50-60% of newly synthesized receptor released at 5-10 nM IGFs. The release of IGF-II/M6P receptors correlated with the levels of secreted cathepsin D in different human breast cancer cells or in rats stable transfectants that are constitutively expressing variable levels of human cathepsin D. IGFs had a stronger effect on IGF-II/M6P receptor release, whereas estradiol treatment preferentially enhanced the release of protease and antiprotease. We thus demonstrate that in human breast cancer cells, IGFs not only act as strong mitogens but also regulate release of alpha 1-antichymotrypsin, IGF-II/M6P-soluble receptor, and cathepsin D; three proteins that potentially regulate cell proliferation and/or invasion.
authors.affiliation: INSERM, Unit 148 on Hormones and Cancer, Montpellier, France.
authors.forename: C
authors.initials: C
authors.lastname: Confort
authors.forename: H
authors.initials: H
authors.lastname: Rochefort
authors.forename: F
authors.initials: F
authors.lastname: Vignon
mesh_terms: D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002402:Cathepsin D / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D011233:Precipitin Tests; D017527:Receptor, IGF Type 2 / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D000514:alpha 1-Antichymotrypsin / Q000378:metabolism*
chemical_list: D017527:Receptor, IGF Type 2; D000514:alpha 1-Antichymotrypsin; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D002402:Cathepsin D